Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 207

1.

Hemodynamic Thresholds for Precapillary Pulmonary Hypertension.

Gerges C, Gerges M, Skoro-Sajer N, Zhou Y, Zhang L, Sadushi-Kolici R, Jakowitsch J, Lang MB, Lang IM.

Chest. 2016 Apr;149(4):1061-73. doi: 10.1378/chest.15-0928. Epub 2016 Jan 12.

2.

A Comparison of Inhaled Nitric Oxide Versus Inhaled Epoprostenol for Acute Pulmonary Hypertension Following Cardiac Surgery.

McGinn K, Reichert M.

Ann Pharmacother. 2016 Jan;50(1):22-6. doi: 10.1177/1060028015608865. Epub 2015 Oct 5.

PMID:
26438636
3.

Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension.

Kimura M, Tamura Y, Takei M, Yamamoto T, Ono T, Kuwana M, Fukuda K, Satoh T.

PLoS One. 2015 Apr 6;10(4):e0121894. doi: 10.1371/journal.pone.0121894. eCollection 2015 Apr 6.

4.
5.

Oral treprostinil for the treatment of pulmonary arterial hypertension.

de Lartigue J.

Drugs Today (Barc). 2014 Aug;50(8):557-65. doi: 10.1358/dot.2014.50.8.2207312.

PMID:
25187906
6.
7.

Catecholamine support at the initiation of epoprostenol therapy in pulmonary arterial hypertension.

Akagi S, Ogawa A, Miyaji K, Kusano K, Ito H, Matsubara H.

Ann Am Thorac Soc. 2014 Jun;11(5):719-27. doi: 10.1513/AnnalsATS.201308-268OC.

PMID:
24716663
8.

Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.

Bergot E, Sitbon O, Cottin V, Prévot G, Canuet M, Bourdin A, de Groote P, Rottat L, Gressin V, Jaïs X, Humbert M, Simonneau G.

Int J Cardiol. 2014 Apr 1;172(3):561-7. doi: 10.1016/j.ijcard.2013.12.313. Epub 2014 Jan 22.

PMID:
24529947
9.

Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.

Small M, Piercy J, Pike J, Cerulli A.

Adv Ther. 2014 Feb;31(2):168-79. doi: 10.1007/s12325-014-0094-z. Epub 2014 Jan 22.

PMID:
24449285
10.

Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study.

Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V.

Am Heart J. 2014 Feb;167(2):218-225.e1. doi: 10.1016/j.ahj.2013.08.008. Epub 2013 Oct 16.

11.

EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.

Sitbon O, Delcroix M, Bergot E, Boonstra AB, Granton J, Langleben D, Subías PE, Galiè N, Pfister T, Lemarié JC, Simonneau G.

Am Heart J. 2014 Feb;167(2):210-7. doi: 10.1016/j.ahj.2013.08.007. Epub 2013 Oct 3.

12.

IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment.

Shirai Y, Tamura Y, Yasuoka H, Satoh T, Kuwana M.

Eur Respir J. 2014 May;43(5):1516-9. doi: 10.1183/09031936.00144013. Epub 2014 Jan 16. No abstract available.

13.

Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis.

Saggar R, Khanna D, Vaidya A, Derhovanessian A, Maranian P, Duffy E, Belperio JA, Weigt SS, Dua S, Shapiro SS, Goldin JG, Abtin F, Lynch JP 3rd, Ross DJ, Forfia PR, Saggar R.

Thorax. 2014 Feb;69(2):123-9. doi: 10.1136/thoraxjnl-2013-204150.

PMID:
24431095
14.

New horizons in pulmonary arterial hypertension therapies.

Galiè N, Ghofrani AH.

Eur Respir Rev. 2013 Dec;22(130):503-14. doi: 10.1183/09059180.00006613. Review.

15.

Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.

Farber HW, Miller DP, Meltzer LA, McGoon MD.

J Heart Lung Transplant. 2013 Nov;32(11):1114-22. doi: 10.1016/j.healun.2013.08.010. Epub 2013 Sep 10.

PMID:
24035189
16.

Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?

Seferian A, Simonneau G.

Eur Respir Rev. 2013 Sep 1;22(129):217-26. doi: 10.1183/09059180.00001713. Review.

17.

Early initiation of prostacyclin in portopulmonary hypertension: 10 years of a transplant center's experience.

Awdish RL, Cajigas HR.

Lung. 2013 Dec;191(6):593-600. doi: 10.1007/s00408-013-9501-5. Epub 2013 Aug 25.

PMID:
23979006
18.

One-year experience with intravenous treprostinil for pulmonary arterial hypertension.

Benza RL, Tapson VF, Gomberg-Maitland M, Poms A, Barst RJ, McLaughlin VV.

J Heart Lung Transplant. 2013 Sep;32(9):889-96. doi: 10.1016/j.healun.2013.06.008.

PMID:
23953817
19.

Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation.

Lopez-Meseguer M, Berastegui C, Monforte V, Bravo C, Domingo E, Roman A.

Transplant Proc. 2013 Jul-Aug;45(6):2347-50. doi: 10.1016/j.transproceed.2013.03.040.

PMID:
23953548
20.

Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis.

Frost AE, Badesch DB, Miller DP, Benza RL, Meltzer LA, McGoon MD.

Chest. 2013 Nov;144(5):1521-9. doi: 10.1378/chest.12-3023.

PMID:
23907471

Supplemental Content

Loading ...
Support Center